Creative Planning Has $796,000 Holdings in Fulgent Genetics, Inc. $FLGT

Creative Planning boosted its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 146.2% in the second quarter, Holdings Channel.com reports. The firm owned 40,021 shares of the company’s stock after acquiring an additional 23,766 shares during the period. Creative Planning’s holdings in Fulgent Genetics were worth $796,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC boosted its position in shares of Fulgent Genetics by 1.6% during the second quarter. Geode Capital Management LLC now owns 513,343 shares of the company’s stock worth $10,207,000 after buying an additional 8,105 shares during the period. Acadian Asset Management LLC boosted its position in Fulgent Genetics by 38.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,117,917 shares of the company’s stock worth $22,208,000 after acquiring an additional 311,976 shares during the last quarter. Campbell & CO Investment Adviser LLC grew its stake in shares of Fulgent Genetics by 51.7% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 27,061 shares of the company’s stock worth $538,000 after acquiring an additional 9,217 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Fulgent Genetics by 22.2% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 305,180 shares of the company’s stock valued at $6,067,000 after purchasing an additional 55,521 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Fulgent Genetics in the second quarter valued at approximately $662,000. 48.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on FLGT. UBS Group upgraded shares of Fulgent Genetics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $20.00 to $30.00 in a report on Tuesday, August 5th. Piper Sandler boosted their price target on shares of Fulgent Genetics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 11th. Wall Street Zen upgraded Fulgent Genetics from a “hold” rating to a “buy” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Wednesday, October 8th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $36.00 target price on shares of Fulgent Genetics in a report on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Fulgent Genetics has a consensus rating of “Hold” and an average price target of $32.00.

Fulgent Genetics Stock Performance

Fulgent Genetics stock opened at $28.40 on Wednesday. The stock has a 50-day simple moving average of $25.11 and a 200 day simple moving average of $22.12. The stock has a market capitalization of $877.90 million, a P/E ratio of -20.43 and a beta of 0.64. Fulgent Genetics, Inc. has a 52 week low of $14.57 and a 52 week high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings data on Friday, November 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.36. The company had revenue of $84.07 million during the quarter, compared to analysts’ expectations of $81.43 million. Fulgent Genetics had a negative return on equity of 2.55% and a negative net margin of 13.62%.Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. Research analysts forecast that Fulgent Genetics, Inc. will post -0.85 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Jian Xie sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $29.10, for a total transaction of $291,000.00. Following the completion of the sale, the chief operating officer owned 349,768 shares in the company, valued at approximately $10,178,248.80. This trade represents a 2.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Hanlin Gao sold 943 shares of Fulgent Genetics stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $29.57, for a total transaction of $27,884.51. Following the sale, the insider directly owned 953,965 shares of the company’s stock, valued at $28,208,745.05. The trade was a 0.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 13,357 shares of company stock valued at $391,361. Company insiders own 33.11% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.